erlotinib hydrochloride has been researched along with Multiple Myeloma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turki, T; Wang, JTL; Wei, Z | 1 |
| Cotreau, MM; Han, M; Hofmeister, CC; Isaacs, R; Jac, J; Papadopoulos, KP; Patnaik, A; Payumo, FC; Ramanathan, RK; Tibes, R; Tolcher, A; Weiss, GJ | 1 |
| Baladandayuthapani, V; Barlogie, B; Cenci, S; Crowley, J; Davis, RE; Esseltine, DW; He, J; Hoering, A; Hunziker, W; Kuiatse, I; Li, B; Li, BZ; Lin, H; Ma, WC; Manasanch, EE; Milan, E; Mulligan, G; Orlowski, RZ; Qi, L; Shah, JJ; Tang, JL; Thomas, SK; Usmani, SZ; Wang, H; Wang, HH; Wang, ZQ; Weber, DM; Xu, J; Yang, J; Yang, L; Zhang, J; Zhang, Q; Zhang, XD | 1 |
| Goldman, B | 1 |
1 trial(s) available for erlotinib hydrochloride and Multiple Myeloma
| Article | Year |
|---|---|
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
3 other study(ies) available for erlotinib hydrochloride and Multiple Myeloma
| Article | Year |
|---|---|
A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Bortezomib; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Computational Biology; Databases, Factual; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Machine Learning; Multiple Myeloma; Triple Negative Breast Neoplasms | 2018 |
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Bortezomib; Cell Line, Tumor; Cysteine Endopeptidases; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Mice, SCID; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays; Zonula Occludens-1 Protein | 2016 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States | 2003 |